You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Lecanemab wins breakthrough therapy designation in Alzheimer’s disease

Biogen and Eisai announced yesterday that their investigational Alzheimer’s disease (AD) treatment lecanemab has received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA).